New Study to Get More Minorities Involved in Genetic Testing
1046 articles
Artificial Intelligence and Early Detection of Pancreatic Cancer
How can AI be used in the early detection of pancreatic cancer? Dr. Michael Rosenthal reviews the current state of the field.
Highlights from the 2025 AACR Annual Meeting
Drugs to target KRAS, better imaging for earlier detection, and cachexia prediction are among the research highlights from AACR 2025.
New Guidelines on the Use of Radiation for Pancreatic Cancer Treatment
New clinical guidelines from the American Society for Radiation Oncology will help clarify the best uses of radiation treatment for pancreatic cancer.
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
Positive Results For Borderline Resectable Disease Pilot Study
Dr. Zev Wainberg provides details on a trial of chemotherapy and immunotherapy for patients with borderline resectable pancreatic cancer.
AACR Virtual Special Conference on Pancreatic Cancer: Day One Highlights
Let’s Win and the Lustgarten Foundation present highlights of Day One of the AACR Virtual Special Conference on Pancreatic Cancer.
A Registry for Those at Risk for Pancreatic Cancer
Dr. Robert Kurtz founded the Pancreatic Tumor Registry at Memorial Sloan Kettering to learn more about the genetic mutations that cause pancreatic cancer.
Personalizing Pancreatic Cancer Treatment
Dr. Mark Ricigliano takes a closer look at the genetics of circulating tumor cells, to personalize pancreatic cancer treatment for the best results.
Advances in Pancreatic Neuroendocrine Tumor (PNET) Treatments
Dr. Diane Reidy-Lagunes outlines the current state of treatments for pancreatic neuroendocrine tumors (PNETs).
“Off-the-Shelf” Vaccine Improves Overall and Average Relapse Survival
Dr. Zev Wainberg provides an update on the effectiveness of a vaccine, with results showing it extends the time to relapse in many patients.
Patients Needed for Clinical Trial/Research Study of Treatment Targeting Immune System
A clinical trial seeks pancreatic cancer patients with the MSI (microsatellite instability) genetic signature, to test an immunotherapy drug.
Finding More Clues about Circulating Tumor DNA
Researcher Dr. Gehan Botrus looks at circulating tumor DNA for genetic information on a patient’s pancreatic cancer to personalize treatment.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
A New Triple Combination for Tumors with BRCA1/2 or PALB2 Mutations
A clinical trial is comparing a two-drug combination with a three-drug combination to see which works better for genetic mutations.
Treating Cancer By Mutation, Not by Tumor Location
Dr. Conan Kinsey outlines the latest basket trials, which focus on tumor mutation, not the location of the cancer.